Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma

Review

(2808) Views  (904) Full article downloads

Authors: Khaldoun Almhanna, Philip A Philip

Published Date November 2009 Volume 2009:2 Pages 261 - 267

DOI: http://dx.doi.org/10.2147/OTT.S5548

Khaldoun Almhanna, Philip A Philip

Department of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA

Abstract: Hepatocellular carcinoma (HCC) is frequently diagnosed in the setting of chronic liver disease and cirrhosis. The median survival after diagnosis is dismal. The treatment options that may offer cure are either resection or liver transplantation. Unfortunately most patients are not eligible for either treatment modality at diagnosis because of advanced stage and underlying liver dysfunction. Until recently, there was no effective systemic therapy for patients with advanced HCC. Sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor and Raf, has shown antitumor activity in patients with advanced HCC in phase III trials. Although objective response is not common, sorafenib promotes disease stabilization and improves overall survival. Sorafenib is well tolerated with a favorable toxicity profile. In this article we review the efficacy and safety data for sorafenib in patients with advanced HCC.

Keywords: sorafenib, hepatocellular carcinoma, hand–foot syndrome

Readers of this article also read: